A deal has been reached between AbbVie Inc. and Boehringer Ingelheim, with the latter agreeing not to launch its biosimilar version of Humira® until July 1, 2023. Under the settlement agreement, Boehringer will receive a non-exclusive license for Humira®'s patents, with AbbVie stating it will make no payments of any form to Boehringer. Earning $20 billion globally in 2018, Humira®, or adalimumab, is the world's top-selling drug and treats rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ulcerative colitis and plaque psoriasis, among other conditions.
